

Supplemental Information

Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells

Pascale André, Caroline Denis, Caroline Soulas, Clarisse Bourbon-Caillet, Julie Lopez, Thomas Arnoux, Mathieu Bléry, Cécile Bonnafous, Laurent Gauthier, Ariane Morel, Benjamin Rossi, Romain Remark, Violette Bresó, Elodie Bonnet, Guillaume Habif, Sophie Guia, Ana Ines Lalanne, Caroline Hoffmann, Olivier Lantz, Jérôme Fayette, Agnès Boyer-Chammard, Robert Zerbib, Pierre Dodion, Hormas Ghadially, Maria Jure-Kunkel, Yannis Morel, Ronald Herbst, Emilie Narni-Mancinelli, Roger B. Cohen, and Eric Vivier

Table S1. Characteristics of the patients with SCCHN analyzed for NKG2A and PD-1 expression on NK and CD8⁺ T cells. Related to Figure 6.

Patient Characteristics N=23		N (%)
Age, median [range]		63 [29-94]
Sex	Female	5 (22%)
	Male	18 (78%)
HPV status	Positive	4 (17%)
	Negative	13 (57%)
	Non available	6 (26%)
Tobacco	Never	4 (17%)
	Former	5 (22%)
	Current	12 (52%)
	Non available	2 (9%)
Tumor site	Oral cavity	10 (43%)
	Oropharynx	2 (9%)
	Larynx	5 (22%)
	Hypopharynx	2 (9%)
	Cutaneous	4 (17%)
History of radiotherapy (overall)	Yes	14 (61%)
	No	9 (39%)
Systemic therapy (last 6 months)	Platinum	2 (9%)
	IO	3 (13%)
	Cetuximab	1 (4%)
	Nivolumab+lirilumab	1 (4%)